Ads
related to: maintenance drugs for ovarian cancer
Search results
Results From The WOW.Com Content Network
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults.It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
[27] it started in 2013 a phase III for metastatic germline BRCA mutated breast cancer. [28] Veliparib June 2014 in phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC). [29] Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [30] It is a PARP1 and PARP2 ...
In the European Union, niraparib is indicated: as monotherapy for the maintenance treatment of adults with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy; and as monotherapy for ...
(Reuters) -The U.S. Food and Drug Administration said on Friday it had granted traditional approval for AbbVie's "guided missile" cancer therapy, Elahere, for patients with a type of ovarian cancer.
Small cell lung cancer, ovarian cancer and cervical cancer: Diarrhoea, myelosuppression, interstitial lung disease and allergy. 1.05 Anthracyclines: Daunorubicin: IV: Inhibits DNA and RNA synthesis by intercalating DNA base pairs. Inhibits DNA repair by inhibiting topoisomerase II. Acute leukaemias
Experts hope treatment will change practice globally for people with no or few treatment options
Ads
related to: maintenance drugs for ovarian cancer